Gri Bio Inc (GRI) Stock Price, Quote & News

Company Profile

GRI Bio, Inc., a clinical-stage biopharmaceutical company, focuses on discovering, developing, and commercializing therapies that target diseases leading to inflammatory, fibrotic, and autoimmune disorders in the United States. Its lead product candidate is GRI-0621, an oral inhibitor of type 1 Natural Killer T cells, which is in phase IIa clinical trial for the treatment of severe fibrotic lung diseases, such as idiopathic pulmonary fibrosis. The company's portfolio also includes GRI-0803, a no...

Industry: Biotechnology

Sector: Healthcare

Phone: 619 400 1170

Website: www.gribio.com

Address:

2223 Avenida de la Playa, Suite 208, La Jolla, United States

NFA_DYOR Jul. 13 at 11:28 PM

$GRI Be careful of scammers who pump, dump on you and short @Joe_088

0 · Reply

NFA_DYOR Jul. 13 at 7:57 PM

$GRI Hehe @Joe_088 was a paid pumper No matter what he'll call it last train to $300

0 · Reply

NFA_DYOR Jul. 13 at 7:56 PM

$GRI Only @Joe_088, the paid pumper says this is mooning soon and its last train join before it leaves

0 · Reply

ka1954 Jul. 13 at 6:22 PM

$GRI for shorts this is and always was an easy target to keep bringing it down forever. too much naked short selling

0 · Reply

NFA_DYOR Jul. 13 at 12:47 PM

$GRI Has it resumed tanking

0 · Reply

NFA_DYOR Jul. 13 at 12:47 PM

$GRI What the hell Its $1.67

0 · Reply

NFA_DYOR Jul. 10 at 8:40 PM

$CMPX 1. ORR - won 2. PFS - Won 3. OS - headlines says missed. There is no concrete evidence of win or loss especially if you debate before vs after cross over. Its simply confounded that might require confirmatory trial maybe 4. Thry have fortress of cash to run operations to 2028 5. Shorts have doubled down their positions because of headlines to 37 million shares shorted - over 25% of float. 6. I am more bulish on this one. I'll wait for Aug to see what institutional ownership looks like, whether they exited or added $GRI i am bearish on this one. Thry have under $10 million in hand, burning quick, about to start expensive phase 2b. An overhang dilution is there $IMVT i am bulish on this one. They are in revenue generating phase $SRPT they have foutress of cash but early phase and high burn rate. Only trading intraday $NVTS they have 36 months of runway cash in hand, they diluted more but at higher price.

0 · Reply

NFA_DYOR Jul. 10 at 6:20 PM

$GRI What the hell No one wants to buy this junk I guess dilution is only solution then repair that with RS

0 · Reply

NFA_DYOR Jul. 10 at 3:13 PM

$GRI @Joe_088 says its the next nvidia and its going to the moon You say its making new lows Who to trust

0 · Reply

ka1954 Jul. 10 at 2:52 PM

$GRI this stock has nothing better to do than to make a new all time low every few days. this stock is just dead

0 · Reply

GRI Bio announces U.S. FDA granted ODD to GRI-0621

Jun 18, 2026, 8:31 AM EDT - 25 days ago

GRI Bio Secures FDA Orphan Drug Designation for GRI-0621 (Tazarotene) in Idiopathic Pulmonary Fibrosis

2026-06-17T15:00:10.000Z - 26 days ago

GRI Bio granted FDA orphan designation for tazarotene

May 18, 2026, 9:15 AM EDT - 2 months ago

GRI Bio to Present at A.G.P.'s Annual Healthcare Company Showcase

May 14, 2026, 8:35 AM EDT - 2 months ago

GRI Bio Reports First Quarter 2026 Financial Results, New Data Reinforcing Differentiated Profile of GRI-0621 in Idiopathic Pulmonary Fibrosis and Highlights Continued Advancement of Differentiated Immune-Modulating Pipeline

May 13, 2026, 7:00 AM EDT - 2 months ago

GRI Bio Quarterly report: Q1 2026

May 13, 2026, 7:00 AM EDT - 2 months ago

GRI Bio Earnings release: Q1 2026

2026-04-08T13:21:10.000Z - 3 months ago

GRI Bio receives UAE patent allowance for inflammatory disease treatments

Apr 8, 2026, 8:30 AM EDT - 3 months ago

GRI Bio Receives Notice of Allowance for UAE Patent Application Covering Novel Type 2 Diverse NKT Cell Agonists for the Treatment of Inflammatory Conditions

Mar 6, 2026, 6:00 AM EST - 4 months ago

GRI Bio Slides: Corporate presentation

Feb 17, 2026, 9:15 AM EST - 5 months ago

GRI Bio CEO, Marc Hertz, Featured in Virtual Investor “What This Means” Segment

Feb 11, 2026, 1:00 PM EST - 5 months ago

GRI Bio Transcript: Corporate Connect Webinar Series

Feb 5, 2026, 9:15 AM EST - 5 months ago

GRI Bio to Participate in the Corporate Connect Webinar Series Virtual Conference Hosted by Webull Financial

2026-02-04T13:50:33.000Z - 5 months ago

GRI Bio sees cash runway into 1Q27

Feb 4, 2026, 8:45 AM EST - 5 months ago

GRI Bio Reiterates Full Year 2025 Financial Results, Strengthens Balance Sheet and Summarizes Key Recent Highlights

Feb 4, 2026, 8:30 AM EST - 5 months ago

GRI Bio Earnings release: Q4 2025

Feb 4, 2026, 8:30 AM EST - 5 months ago

GRI Bio Annual report: Q4 2025

Jan 30, 2026, 7:00 AM EST - 5 months ago

GRI Bio Registration statement: Registration Filing

2026-01-30T11:11:17.000Z - 5 months ago

GRI Bio files $250M mixed securities shelf

2026-01-28T14:41:21.000Z - 5 months ago

GRI Bio Inc trading resumes

2026-01-28T14:35:28.000Z - 5 months ago

GRI Bio Inc trading halted, volatility trading pause

2026-01-28T13:56:26.000Z - 5 months ago

GRI Bio delivers additional data from Phase 2a study of GRI-0621

Jan 28, 2026, 8:45 AM EST - 5 months ago

GRI Bio Delivers Compelling New Phase 2a Gene Expression Data Demonstrating Improvements in Key Drivers of Fibrosis and Lung Repair in IPF

2026-01-26T13:35:51.000Z - 6 months ago

GRI Bio secures U.S. composition of matter patent

2026-01-24T00:50:50.000Z - 6 months ago

GRI Bio Inc trading halted, news pending

2026-01-21T21:25:40.000Z - 6 months ago

GRI Bio announces 1-for-28 reverse stock split

Jan 21, 2026, 4:01 PM EST - 6 months ago

GRI Bio Announces Reverse Stock Split

Jan 15, 2026, 9:00 AM EST - 6 months ago

GRI Bio Transcript: EGM 2026

2026-01-08T13:39:21.000Z - 6 months ago

GRI Bio announces data from Phase 2a study in Idiopathic Pulmonary Fibrosis

Dec 29, 2025, 7:00 AM EST - 7 months ago

GRI Bio Proxy statement: Proxy Filing

Dec 19, 2025, 7:00 AM EST - 7 months ago

GRI Bio Proxy statement: Proxy Filing

Dec 12, 2025, 4:05 PM EST - 7 months ago

GRI Bio Announces Closing of $8.0 Million Public Offering

2025-12-11T14:20:13.000Z - 7 months ago

GRI Bio prices 10.67M shares at 75c in public offering

Dec 11, 2025, 9:15 AM EST - 7 months ago

GRI Bio Announces Pricing of $8,000,000 Million Public Offering

2025-12-10T21:41:18.000Z - 7 months ago

GRI Bio announces GRI-0621-IPF-02 trial met primary, secondary endpoints

Dec 10, 2025, 4:05 PM EST - 7 months ago

GRI Bio Announces Positive Topline Data from its Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Dec 10, 2025, 7:00 AM EST - 7 months ago

GRI Bio Registration statement: Registration Filing

2025-12-08T13:25:31.000Z - 7 months ago

GRI Bio files to sell 5.13M shares of common stock, warrants

Dec 8, 2025, 7:00 AM EST - 7 months ago

GRI Bio Registration statement: Registration Filing

Nov 14, 2025, 7:00 AM EST - 8 months ago

GRI Bio Quarterly report: Q3 2025

2025-09-11T12:50:15.000Z - 10 months ago

GRI Bio reports six-week lung function data in Phase 2a study of GRI-0621

Sep 11, 2025, 8:45 AM EDT - 10 months ago

GRI Bio Reports 6-Week Interim Lung Function Data in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

Sep 9, 2025, 3:00 PM EDT - 10 months ago

GRI Bio Transcript: H.C. Wainwright 27th Annual Global Investment Conference

Aug 14, 2025, 4:00 PM EDT - 11 months ago

GRI Bio Quarterly report: Q2 2025

Aug 14, 2025, 9:15 AM EDT - 11 months ago

GRI Bio to Present at the Webull Financial Corporate Connect Webinar Series: Biotech/MedTech

Jul 31, 2025, 1:50 PM EDT - 1 year ago

GRI Bio CEO, Marc Hertz, Participates in Virtual Investor “What This Means” Segment

2025-07-31T13:05:39.000Z - 1 year ago

GRI Bio reports 6-week interim biomarker results from Phase 2a study in IPF

Jul 22, 2025, 8:45 AM EDT - 1 year ago

GRI Bio Participates in the Virtual Investor “What's Your Story” Summer Spotlight On-Demand Conference

Jul 11, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Proxy statement: Proxy Filing

Jul 6, 2025, 6:00 PM EDT - 1 year ago

GRI Bio Slides: Corporate Presentation

2025-07-01T12:50:17.000Z - 1 year ago

GRI Bio completes enrollment in Phase 2a study of GRI-0621

Jul 1, 2025, 8:45 AM EDT - 1 year ago

GRI Bio Completes Enrollment in Phase 2a Study of GRI-0621 for the Treatment of Idiopathic Pulmonary Fibrosis (“IPF”)

2025-06-26T12:06:08.000Z - 1 year ago

GRI Bio reports 6-week interim safety data from Phase 2a study of GRI-0621

Jun 26, 2025, 8:00 AM EDT - 1 year ago

GRI Bio's GRI-0621 Demonstrates Encouraging Safety Results at Planned Interim 6-Week Analysis in Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 21, 2025, 2:40 PM EDT - 1 year ago

GRI Bio Transcript: Alliance Global Partners Healthcare Company Showcase

May 21, 2025, 2:40 PM EDT - 1 year ago

GRI Bio Transcript: A.G.P.'s Virtual Healthcare Company Showcase 2025

May 21, 2025, 9:15 AM EDT - 1 year ago

GRI Bio to Participate in the Virtual Investor Closing Bell Series

May 15, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Reports First Quarter 2025 Financial Results and Confirms GRI-0621 Phase 2a IPF Trial on Track for 6-Week Interim Data in Q2 2025 and Topline Data in Q3 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

GRI Bio Quarterly report: Q1 2025

May 15, 2025, 8:30 AM EDT - 1 year ago

GRI Bio Earnings release: Q1 2025

May 8, 2025, 8:45 AM EDT - 1 year ago

GRI Bio's Interim Biomarker Data Demonstrate Positive Trend Towards Anti-Fibrotic Effect of GRI-0621 in First Twelve Patients of Ongoing Phase 2a Study in Idiopathic Pulmonary Fibrosis (“IPF”)

May 7, 2025, 9:15 AM EDT - 1 year ago

GRI Bio Continues to Drive Enrollment in Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Apr 16, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Announces Abstract Selected for Poster Discussion Session at the 2025 American Thoracic Society (ATS) International Conference

Apr 2, 2025, 4:05 PM EDT - 1 year ago

GRI Bio Announces Closing of $5.0 Million Public Offering

Apr 1, 2025, 11:15 AM EDT - 1 year ago

GRI Bio Announces Pricing of $5.0 Million Public Offering

Mar 31, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Bolsters Intellectual Property Portfolio with Granting of Two Global Patents for Europe and Japan

Mar 26, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Registration statement: Registration Filing

Mar 25, 2025, 8:00 AM EDT - 1 year ago

GRI Bio Registration statement: Registration Filing

Mar 18, 2025, 9:05 AM EDT - 1 year ago

GRI Bio Participates in a Virtual Investor CEO Connect Segment

Mar 17, 2025, 8:05 AM EDT - 1 year ago

GRI Bio Reports Full Year 2024 Financial Results and Reiterates Expected Clinical Data Readouts in 2025 for Ongoing Phase 2a Study of GRI-0621 in Idiopathic Pulmonary Fibrosis (“IPF”)

Mar 14, 2025, 7:30 AM EDT - 1 year ago

GRI Bio Earnings release: Q4 2024

Mar 14, 2025, 7:30 AM EDT - 1 year ago

GRI Bio Annual report: Q4 2024

Mar 11, 2025, 8:35 AM EDT - 1 year ago

GRI Bio Regains Compliance with Nasdaq's Minimum Bid Price Rule

Feb 19, 2025, 9:00 AM EST - 1 year ago

GRI Bio, Inc. Participates in the Virtual Investor “Top 5 for ‘25” On-Demand Conference

Jan 17, 2025, 7:00 AM EST - 1 year ago

GRI Bio Proxy statement: Proxy Filing

Jan 7, 2025, 7:00 AM EST - 1 year ago

GRI Bio Proxy statement: Proxy Filing

Dec 23, 2024, 9:00 AM EST - 1 year ago

GRI Bio Announces European Patent Office Issued a Decision to Grant Notice for Patent Covering GRI-0803 and Its Library of 500+ Proprietary Compounds

Dec 6, 2024, 7:00 AM EST - 1 year ago

GRI Bio Slides: Corporate Presentation

Nov 21, 2024, 8:45 AM EST - 1 year ago

GRI Bio Showcases GRI-0621's Potential to Reduce Inflammation, Type 1 Cytokines and Reduce Hepatic Fibrosis in Idiopathic Pulmonary Fibrosis (IPF)

Nov 14, 2024, 4:20 PM EST - 1 year ago

GRI Bio Reports Third Quarter 2024 Financial Results and Outlines Progress Towards Clinical Data Readout of GRI-0621 in Ongoing Phase 2a Study for Idiopathic Pulmonary Fibrosis

Nov 14, 2024, 7:00 AM EST - 1 year ago

GRI Bio Quarterly report: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

GRI Bio Earnings release: Q3 2024

Nov 14, 2024, 7:00 AM EST - 1 year ago

GRI Bio Registration statement: Registration Filing

Oct 24, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Raises a Total of $13.9 Million in Gross Proceeds Since the Beginning of 2024

Oct 21, 2024, 5:35 PM EDT - 1 year ago

GRI Bio Announces Exercise of Warrants

Oct 16, 2024, 8:45 AM EDT - 1 year ago

GRI Bio Presents Positive Preclinical Data Demonstrating GRI-0621's Ability to Inhibit Invariant Natural Killer T (iNKT) Cell Activity and Reduce Important Inflammatory and Fibrotic Drivers in Idiopathic Pulmonary Fibrosis (IPF)

Sep 30, 2024, 8:30 AM EDT - 1 year ago

GRI Bio Granted Japan Patent for Proprietary Natural Killer T (NKT) Cell Modulators for Prevention and Treatment of Inflammatory Conditions

Sep 25, 2024, 8:45 AM EDT - 1 year ago

GRI Bio (NASDAQ: GRI) to Participate in a Virtual Investor CEO Connect Segment

Sep 5, 2024, 8:45 AM EDT - 2 years ago

GRI Bio to Present at the H.C. Wainwright 26th Annual Global Investment Conference

Sep 4, 2024, 8:45 AM EDT - 2 years ago

GRI Bio to Present at the 2024 European Respiratory Congress

Aug 23, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Aug 23, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Aug 16, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Aug 14, 2024, 8:05 AM EDT - 2 years ago

GRI Bio Reports Second Quarter 2024 Financial Results and Provides Corporate Update

Aug 14, 2024, 7:00 AM EDT - 2 years ago

GRI Bio Quarterly report: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

GRI Bio Earnings release: Q2 2024

Aug 14, 2024, 7:00 AM EDT - 2 years ago

GRI Bio Slides: Q2 2024

Aug 2, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Jul 23, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Proxy statement: Proxy Filing

Jul 15, 2024, 9:05 AM EDT - 2 years ago

GRI Bio (NASDAQ: GRI) to Participate in the Virtual Investor Lunch Break Series

Jul 11, 2024, 9:20 AM EDT - 2 years ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment

Jul 8, 2024, 9:05 AM EDT - 2 years ago

GRI Bio Regains Compliance with Nasdaq

Jul 2, 2024, 9:05 AM EDT - 2 years ago

GRI Bio Announces Publication of Positive Preclinical Data from Lead Program GRI-0621 in the American Journal of Respiratory and Critical Care Medicine

Jul 1, 2024, 8:45 AM EDT - 2 years ago

GRI Bio to Present at the 8th Annual IPF Summit

Jun 28, 2024, 4:05 PM EDT - 2 years ago

GRI Bio Announces Closing of $4.0 Million Public Offering

Jun 27, 2024, 9:00 AM EDT - 2 years ago

GRI Bio Announces Korea Patent Granted for Proprietary Natural Killer T (NKT) Cell Modulators

Jun 26, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Registration statement: Registration Filing

Jun 26, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Registration statement: Registration Filing

Jun 20, 2024, 8:00 AM EDT - 2 years ago

GRI Bio Registration statement: Registration Filing

May 22, 2024, 9:15 AM EDT - 2 years ago

GRI Bio (NASDAQ: GRI) Participates in Virtual Investor “What This Means” Segment Highlighting Positive Preclinical Data from Idiopathic Pulmonary Fibrosis (IPF) and Systemic Lupus Erythematosus (SLE) Programs

May 21, 2024, 8:35 AM EDT - 2 years ago

GRI Bio Presents Positive Preclinical Data from Pipeline of NKT Cell Modulators in Development for the Treatment of Systemic Lupus Erythematosus (SLE)

NFA_DYOR Jul. 13 at 11:28 PM

$GRI Be careful of scammers who pump, dump on you and short @Joe_088

0 · Reply

NFA_DYOR Jul. 13 at 7:57 PM

$GRI Hehe @Joe_088 was a paid pumper No matter what he'll call it last train to $300

0 · Reply

NFA_DYOR Jul. 13 at 7:56 PM

$GRI Only @Joe_088, the paid pumper says this is mooning soon and its last train join before it leaves

0 · Reply

ka1954 Jul. 13 at 6:22 PM

$GRI for shorts this is and always was an easy target to keep bringing it down forever. too much naked short selling

0 · Reply

NFA_DYOR Jul. 13 at 12:47 PM

$GRI Has it resumed tanking

0 · Reply

NFA_DYOR Jul. 13 at 12:47 PM

$GRI What the hell Its $1.67

0 · Reply

NFA_DYOR Jul. 10 at 8:40 PM

0 · Reply

NFA_DYOR Jul. 10 at 6:20 PM

$GRI What the hell No one wants to buy this junk I guess dilution is only solution then repair that with RS

0 · Reply

NFA_DYOR Jul. 10 at 3:13 PM

$GRI @Joe_088 says its the next nvidia and its going to the moon You say its making new lows Who to trust

0 · Reply

ka1954 Jul. 10 at 2:52 PM

$GRI this stock has nothing better to do than to make a new all time low every few days. this stock is just dead

0 · Reply

NFA_DYOR Jul. 10 at 12:56 PM

$GRI What the hell Its stuck here No institutions buying Only retail fomo

0 · Reply

NFA_DYOR Jul. 10 at 8:13 AM

$GRI @Joe_088 GRI Bio is heavily subjected to online hype, and it is a textbook target for micro-cap "pump and dump" cycles.

0 · Reply

NFA_DYOR Jul. 10 at 8:10 AM

$GRI @Joe_088 Why It Fits the "Junk Stock" DescriptionDestructive Share Dilution: Companies in this position survive by constantly issuing new shares to raise cash. This dilutes the value of existing shares, meaning long-term investors watch their ownership stake dwindle to almost nothing.The Reverse Split Trap: GRI Bio already executed a massive 1-for-28 reverse stock split to artificially pump its share price back over $1.00 just to avoid getting kicked off the Nasdaq exchange. This is a classic hallmark of a distressed, low-quality stock.Going Concern Risk: Their own auditors have officially warned that the company may not survive because it is losing millions of dollars and burning through its tiny cash reserves.Extreme Volatility: Its ultra-low market cap makes it a prime target for day traders and "pump and dump" cycles, where the price might spike 50% on minor news and crash 60% the next day.

0 · Reply

NFA_DYOR Jul. 10 at 8:09 AM

$GRI @Joe_088 Listing & Dilution Risks: The company had to execute a 1-for-28 reverse stock split to maintain its Nasdaq listing compliance. Relying heavily on public offerings and warrants creates high dilution risks for current equity

0 · Reply

NFA_DYOR Jul. 10 at 8:08 AM

$GRI @Joe_088 Looming Patent Cliff: The core intellectual property for its primary pipeline candidates (GRI-0621 and GRI-0803) is set to expire around 2032. Because drug development takes years, a buyer would have a very narrow window to maximize profits before generic competition enters.

0 · Reply

NFA_DYOR Jul. 10 at 8:08 AM

$GRI @Joe_088 Early Clinical Stage: Phase 2a data is a solid proof of concept, but it is still highly preliminary. Big Pharma usually prefers to see larger, randomized Phase 2b data before deploying capital for a full corporate acquisition

0 · Reply

NFA_DYOR Jul. 10 at 8:08 AM

$GRI @Joe_088 Severe Financial Distress: GRI Bio is burning cash rapidly and missed its Q1 2026 earnings estimates by over 76%. Its auditors issued a "going concern" warning due to an accumulated deficit exceeding $51 million. Big Pharma companies know this and often choose to wait out financially distressed biotechs to buy their intellectual property out of bankruptcy or at a steeper discount.

0 · Reply

NFA_DYOR Jul. 10 at 8:07 AM

$GRI @Joe_088 Despite the low price tag, several critical factors lower the probability of an immediate takeover:

0 · Reply

NFA_DYOR Jul. 9 at 7:19 PM

$GRI Bro you say this is going to be brought Big pharma exploit desperation and wait fornconpanies to cripple and come to its knees at filthy cheap

0 · Reply

NFA_DYOR Jul. 9 at 7:18 PM

$GRI Bro You trust these ratios or think next time itll be 1:2000? @Joe_088

0 · Reply

NFA_DYOR Jul. 9 at 7:16 PM

$GRI Buyout - big pharma exploit that fact that conpanies are desperate, will wait until its worthless than buy it cheap @Joe_088

0 · Reply

NFA_DYOR Jul. 9 at 7:15 PM

$GRI Then a huge RS

0 · Reply

Market Cap	3.08M
Revenue (ttm)	0.00
Net Income (ttm)	-11.96M
EPS (ttm)	N/A
PE Ratio	0.00
Forward PE	N/A
Profit Margin	0.00%
Debt to Equity Ratio	0.00

Volume	54,700
Avg Vol	71,686
Day's Range	N/A - N/A
Shares Out	1.77M
Stochastic %K	10%
Beta	-1.21
Analysts	Sell
Price Target	$21.00